Results 81 to 90 of about 20,950 (257)
Effectiveness and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis in real‐world practice
Experimental Dermatology, 2023 A number of randomized controlled trials and real‐world studies have demonstrated the effectiveness and safety of secukinumab in the treatment of moderate to severe psoriasis, whereas data on a large cohort of Chinese patients in long‐term real‐world ...Jian Zhou, Yuan Yuan, Yanhua Liu, Mengyang Chu, Huan Liu, Qian Liu, Rui Wang, S. Shao, G. Wang, Chen Yu +9 moresemanticscholar +1 more sourceReal‐World, Prospective, Multicenter Outcomes to Brodalumab Treatment in Patients With Moderate‐to‐Severe Psoriasis in Greece (The RESOLVE Study)
JEADV Clinical Practice, EarlyView.RESOLVE was a prospective, real‐world study in patients with moderate‐to‐severe psoriasis treated with brodalumab. At Week 12, 76.4% achieved PASI ≤ 3, 53.5% PASI100, and 71.5%/54.2% achieved sPGA0/1 and sPGA 0, respectively. At Week 52, 96.1% achieved sPGA success (clear/almost clear). Furthermore, at Week 52, mean DLQI scores decreased by 12.6 ± 6.2, Electra Nicolaidou, Pantelis Panagakis, Dimitrios Xekardakis, Natalia Rompoti, Marina Papoutsaki, Ioanna Lefaki, Kanella Kalapothakou, Despina Exadactylou, Athanasios Chaniotis, Vasiliki Chasapi, Alexander Stratigos +10 morewiley +1 more sourceLong-term efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa: Week 104 results from the SUNSHINE and SUNRISE extension trial.
British Journal of DermatologyBACKGROUND
SUNSHINE and SUNRISE demonstrated sustained clinical efficacy of secukinumab in patients with moderate-to-severe hidradenitis suppurativa (HS) through 52 weeks.A. Kimball, F. Bechara, A. Badat, E. Giamarellos‐Bourboulis, Alice B. Gottlieb, G. Jemec, Ziad Reguiai, Axel P. Villani, Ivette Alarcon, Amita Bansal, Francesca Gasperoni, R. Martin, B. Paguet, Lorenz Uhlmann, Hichem Zouater, Shoba Ravichandran, Afsaneh Alavi +16 moresemanticscholar +1 more sourceLong-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 Study
Clinical, Cosmetic and Investigational Dermatology, 2023 Purpose SUPREME, a phase IIIb study conducted in Italy, demonstrated safety and high efficacy of secukinumab for up to 72 weeks in patients with moderate-to-severe plaque-type psoriasis. SUPREME 2.0 study aimed to provide real-world data on the long-term F. Russo, M. Galluzzo, L. Stingeni, S. Persechino, L. Zichichi, Andrea Conti, C. Giofré, V. Dini, Martina Vispi, L. Atzori, Angelo Cattaneo, A. Parodi, F. Bardazzi, G. Stinco, P. Dapavo, G. Girolomoni, M. L. Musumeci, M. Papini, M. Venturini, S. Dastoli, S. di Nuzzo, M. Fargnoli, G. Pagnanelli, N. Bernardini, Daniele Gambini, P. Malagoli, C. Mazzatenta, K. Peris, I. Zalaudek, G. Fabbrocini, F. Loconsole, Camilla Vassallo, Lucia Pietroleonardo, F. Prignano, C. Franchi, A. Offidani, C. Bonifati, V. Di Lernia, Giovanni Gigante, M. Bartezaghi, Matteo Franchi, Paola Ursoleo, E. Aloisi +42 moresemanticscholar +1 more sourceTargeting inflammatory pathways in axial spondyloarthritis. [PDF]
, 2019 The triggers and pathogenesis of axial spondyloarthritis (axSpA) are not yet completely understood. However, therapeutic agents targeting tumor necrosis factor-α and interleukin-17 inflammatory pathways have proven successful in suppressing many of the ...Furst, Daniel E, Louie, James Score Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation [PDF]
, 2017 Background: Psoriasis is a chronic inflammatory disease that predominantly affects the skin. Adalimumab (HUMIRA®, AbbVie, Maidenhead, UK), etanercept (Enbrel®, Pfizer, New York, NY, USA) and ustekinumab (STELARA®, Janssen Biotech, Inc., Titusville, NJ ...AbbVie, Ali, All Wales Medicines Strategy Group, All Wales Therapeutics and Toxicology Centre, Altmeyer, Amgen Inc, Amgen Inc, Amgen Inc, Amgen Inc, Amornpinyokeit, Asahina, Balzola, Barker, Basko-Plluska, Basra, Benoit, Berth-Jones, Bigby, Bissonnette, Bonafede, Brunasso, Brănişteanu, Burden-Teh, Burden-Teh, Burden-Teh, Burmester, Burmester, Centre for Reviews and Dissemination, Chaudhari, Chen, Chingcuanco, Chiu, Christiansen, Christophers, Cooper, Corbett, da Silva, Dakin, de Jager, De Jager, de Jager, Department of Health, Dias, Dias, Dias, Dias, DiMarco, Dixon, Dolan, Driessen, Eissing, Elder, Elewski, Esposito, European Medicines Agency, European Medicines Agency, European Medicines Agency, European Medicines Agency, European Medicines Agency, European Medicines Agency, European Medicines Agency, European Medicines Agency, European Medicines Agency, EuroQol Research Foundation, Faerber, Fallah Arani, Famenini, Farhi, Feldman, Flytström, Fonia, Garber, Geiger, Gisondi, Gniadecki, Gniadecki, Gordon, Gordon, Gottlieb, Gottlieb, Greater Medicines Management Group, Griffiths, Guenther, Heydendael, Heydendael, Higgins, Higgins, Ho, Holme, Howe, Ibfelt, Ibrahim, Igarashi, Italian Multicenter Study Group on Cyclosporin in Psoriasis, Janagond, Jankovic, Janssen Biotech, Inc, Janssen Research & Development, LLC, Janssen Research & Development, LLC, Janssen Research & Development, LLC, Janssen-Cilag International, Joint Formulary Committee, Khan, Kim, Kim, Kimball, Klufas, Koo, Kragballe, Krueger, Krueger, Kurd, Laburte, Landells, Landells, Landells, Langley, Langley, Langley, Langley, Lara-Corrales, Lebwohl, Lebwohl, Lefebvre, Lefebvre, Leman, Leonardi, Leonardi, Levy, Lewis-Jones, Lu, Lynde, López-Ferrer, Mahé, Meffert, Melis, Menter, Menter, Menter, MIMS, Moher, National Horizon Scanning Centre, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, NIHR Horizon Scanning Centre, NIHR Horizon Scanning Centre, Norman, Novartis Pharmaceuticals, Novartis Pharmaceuticals, Office for National Statistics, Oostveen, Paller, Paller, Paller, Paller, Paller, Paller, Paller, Paller, Paller, Papp, Papp, Papp, Papp, Papp, Papp, Papp, Papp, Papp, Parisi, Park, Paul, Pereira, Pfizer, Pfizer, Phillipp, Puig, Ranjan, Reich, Reich, Rencz, Revicki, Richardson, Rodgers, Romero-Maté, Royal College of Paediatrics and Child Health, Ruano, Ruzicka, Ryan, Salek, Sanclemente, Saurat, Schabert, Seminara, Seyger, Shah, Siegfried, Siegfried, Signorovitch, Smith, Soliman, Strand, Strohal, Strohal, Sutton, Takashima, Tanew, Tarp, Torii, Tsai, Umezawa, Upton, US Food and Drug Administration, van de Kerkhof, van Reenen, Varni, Varni, Varni, Vencovsky, Vickers, Warren, Warren, Woods, Woolacott, Wu, Wyeth, Yang, Young, Zachariae, Zhu +239 morecore +3 more sourcesFour-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohort
Arthritis Research & Therapyto evaluate over a 48-month follow-up period the: 1) long-term effectiveness and safety; 2) drug retention rate (DRR); 3) impact of comorbidities and bDMARDs line on MDA and DAPSA remission/low disease activity (LDA) of secukinumab in a multicenter ...R. Ramonda, M. Lorenzin, M. Chimenti, Fabiola Atzeni, A. Semeraro, S. D’Angelo, C. Selmi, A. Ortolan, A. Marchesoni, Maria Manara, M. M. Luchetti Gentiloni, Leonardo Santo, Carlo Salvarani, Alberto Cauli, Maurizio Rossini, G. Amato, G. Cozzi, L. Scagnellato, M. Ferraioli, Antonio Carriero, E. Fracassi, Francesco Giorgio, Andrea Doria, Rosario Foti, A. Carletto, Roberta Mariagrazia Maria Sole Fabiola Angelo Salvatore Ca Ramonda Lorenzin Chimenti Atzeni Semeraro D’Angelo, R. Foti, E. Visalli, Y. Dal Bosco, De Lucia Francesco, Cesaro Siracusano, Sergio Collela, Nicoletta Luciano, V. Paci, Giulia Marchionni, N. Girolimetto, A. Floris, G. Citriniti, G. Striani, Antonio Carriero, G. Guidelli +40 moresemanticscholar +1 more source
